MuciMed's Convertible Note Round

MuciMed raised a round of funding on November 28, 2006.

MuciMed is focused on developing and commercializing mucin proteins for the treatment of gastrointestinal (GI) disease. MuciMed's objective is to develop MUC17, a novel protein therapeutic, for the im…

Articles about MuciMed's Convertible Note Round: